Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Recombinant Protein / CD Molecules

Recombinant Human CD277/BTN3A1 Protein, C-Fc

Catalog #:   EHA13501 Specific References (30) DATASHEET
Applications: ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Expression system: Mammalian Cells
Accession: O00481
Protein length: Met1-Gly254
Overview

Catalog No.

EHA13501

Expression system

Mammalian Cells

Species

Homo sapiens (Human)

Protein length

Met1-Gly254

Predicted molecular weight

53.88 kDa

Nature

Recombinant

Endotoxin level

Please contact with the lab for this information.

Purity

>90% as determined by SDS-PAGE.

Accession

O00481

Applications

ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress

Form

Lyophilized

Storage buffer

Lyophilized from a solution in PBS pH 7.4, 1mM EDTA, 4% Trehalose, 1% Mannitol.

Reconstitution

Reconstitute in sterile water for a stock solution.A copy of datasheet will be provided with the products, please refer to it for details.

Shipping

In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Alternative Names

BTF5, BTN3A1, Butyrophilin subfamily 3 member A1, CD277

Data Image
  • SDS-PAGE
    SDS PAGE for recombinant Human CD277/BTN3A1 Protein
  • Bioactivity
    Detects Human CD277/BTN3A1 Antibody (103.2#) in indirect ELISAs.
References

Disrupting the balance between activating and inhibitory receptors of γδT cells for effective cancer immunotherapy., PMID:40456901

Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells., PMID:38012415

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer., PMID:37179293

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?, PMID:36212445

CD277 agonist enhances the immunogenicity of relapsed/refractory acute myeloid leukemia towards Vδ2+ T cell cytotoxicity., PMID:35920929

Ligand-induced interactions between butyrophilin 2A1 and 3A1 internal domains in the HMBPP receptor complex., PMID:35081362

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?, PMID:33925671

BTN3A1 governs antitumor responses by coordinating αβ and γδ T cells., PMID:32820120

γ9δ2T cell diversity and the receptor interface with tumor cells., PMID:32484803

Alpaca (Vicugna pacos), the first nonprimate species with a phosphoantigen-reactive Vγ9Vδ2 T cell subset., PMID:32139608

Checkpoint Genes at the Cancer Side of the Immunological Synapse in Bladder Cancer., PMID:31869744

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma., PMID:30906655

Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells., PMID:30871629

Human Vγ9Vδ2 T cells show potent antitumor activity against zoledronate-sensitized OSCC cell lines., PMID:30722122

A power law function describes the time- and dose-dependency of Vγ9Vδ2 T cell activation by phosphoantigens., PMID:30391478

Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells., PMID:29731756

Regulation of Human γδ T Cells by BTN3A1 Protein Stability and ATP-Binding Cassette Transporters., PMID:29670629

The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region., PMID:28705810

BTN3A1-antibodies and phosphoantigens: TCRVγ9Vδ2 "see" the difference., PMID:28597565

Butyrophilin 3A (BTN3A, CD277)-specific antibody 20.1 differentially activates Vγ9Vδ2 TCR clonotypes and interferes with phosphoantigen activation., PMID:28386905

Butyrophilin 3A/CD277-Dependent Activation of Human γδ T Cells: Accessory Cell Capacity of Distinct Leukocyte Populations., PMID:27619996

Peripheral blood-derived, γ9δ2 t cell-enriched cell lines from glioblastoma multiforme patients exert anti-tumoral effects in vitro., PMID:27049073

Regulation of Immunity by Butyrophilins., PMID:26772212

Inhibition of human γδ T cell proliferation and effector functions by neutrophil serine proteases., PMID:25345993

Phosphoantigens and butyrophilin 3A1 induce similar intracellular activation signaling in human TCRVγ9+ γδ T lymphocytes., PMID:24925024

Butyrophilin 3A1 plays an essential role in prenyl pyrophosphate stimulation of human Vγ2Vδ2 T cells., PMID:23833237

The molecular basis for modulation of human Vγ9Vδ2 T cell responses by CD277/butyrophilin-3 (BTN3A)-specific antibodies., PMID:22846996

Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset., PMID:22767497

Differential role for CD277 as a co-regulator of the immune signal in T and NK cells., PMID:21918970

CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells., PMID:21113407

Datasheet
$ 480
Product specifications
100 μg 480 1 mg 2880

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Recombinant Human CD277/BTN3A1 Protein, C-Fc [EHA13501]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only